Neuropeptide Y (13-36), amide, human

[C@@H](CC1=CC=C(O)C=C1)(NC([C@H](CC2=CN=CN2)NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H](CC3=CC=C(O)C=C3)NC([C@H](CC4=CC=C(O)C=C4)NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC(=O)[C@@H]5CCCN5)C)=O)CCC(O)=O)=O)CC(O)=O)=O)CCSC)=O)C)=O)CCCNC(=N)N)=O)=O)=O)CO)=O)C)=O)CC(C)C)=O)CCCNC(=N)N)=O)=O)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](CC6=CC=C(O)C=C6)C(N)=O)=O)CCCNC(=N)N)=O)CCC(N)=O)=O)CCCNC(=N)N)=O)[C@@H](C)O)=O)[C@H](CC)C)=O)CC(C)C)=O)CC(N)=O)=O)[C@H](CC)C)=O

[1]Aguirre JA, et al. Centrally injected neuropeptide Y (13-36) produces vasopressor effects and antagonizes the vasodepressor action of neuropeptide Y (1-36) in the awake male rat. Neurosci Lett. 1990 Oct 2;118 (1) :5-8.|[2]Daiki Ueda, et al. Increase in neuropeptide Y activity impairs social behaviour in association with glutamatergic dysregulation in diabetic mice. Br J Pharmacol. 2021 Feb;178 (3) :726-740.